Disclaimer This information is intended for educational purposes and should not replace professional medical advice
As such, we conclude that rs10305420 is probably the causal variant
doi:10.1371/journal.ppat.1008030 [19] Maruyama T, Maruyama N, Higuchi T, et al
Patients should avoid self-sourcing it online and should speak with a qualified provider about safer, medically supervised options
doi: 10.3748/wjg.v18.i36.5065 246 MikhailovaTLSishkovaEPoniewierkaEZhidkovKPBakulinIGKupcinskasLet al
GLP-1 receptor agonists and renal outcomes Based on the US FDA industry guidance issued in 2008, all new glucose-lowering agents were required to perform a large-sized placebo-controlled cardiovascular outcome/safety trial, usually conducted in people with T2D with pre-existent or at high-risk of developing CVD